Integral Molecular Unveils Paratope-PLUS™ for Enhanced Antibody Patenting
This innovative technology aligns with new USPTO guidelines for writing robust antibody patent claims and supports advanced antibody engineering for unique intellectual property.
Integral Molecular has launched a revolutionary service named Paratope-PLUS™. This new technology aims to improve antibody patent claims significantly, responding to the recent updates in U.S. patent regulations. Paratope-PLUS™ utilizes a process called CDR-scanning, which employs high-throughput mutagenesis to optimize patenting strategies for antibodies. Through this method, researchers can identify novel claim sets that enhance their intellectual property.
By mutating each residue of an antibody's CDRs (Complementarity Determining Regions) into all 19 other amino acids, Paratope-PLUS™ uncovers every important variant that can either preserve or improve the antibody's function. This technique helps to define antibody 'genus' claims broadly around a common structural element known as the paratope, which consists of the residues that interact directly with the target. This innovative approach fulfills critical requirements set forth by the U.S. Patent and Trademark Office (USPTO), ensuring thorough enablement and proper written describability of the antibody designs.
CEO Benjamin Doranz emphasizes the urgency of such solutions: "The Supreme Court's recent ruling has created complexity in patenting broad functional claims for antibodies, thus presenting a significant challenge for intellectual property. With more than 20 years dedicated to high-throughput protein mutagenesis and antibody evaluation, Integral Molecular is thrilled to introduce a service capable of delivering substantial protection for antibody-related intellectual property, along with insights that can lead to the development of better therapeutics."
The Key Features of Paratope-PLUS™ Include:
- Comprehensive expression and binding analyses for each antibody variant.
- A defined genus of structurally related antibodies that comply with enablement and descriptive requirements necessary for expansive patent claims.
- Extensive data on variants exhibiting enhanced expression, binding, and development potential, laying the foundation for antibody engineering and novel intellectual property claims.
For developers focused on antibody innovations and interested in exploring CDR-scanning, Integral Molecular is ready to provide information and assistance.
About Integral Molecular
Integral Molecular is recognized as a pioneering force in the creation of transformative technologies aimed at advancing therapeutic discovery against challenging protein targets. With an extensive background spanning over 20 years, the organization has concentrated its efforts on antibodies, membrane proteins, and viral agents. Integral Molecular's innovative solutions have been effectively utilized across the drug discovery pipelines of over 600 biotech and pharmaceutical companies, aiding in the development of novel therapies targeting diverse conditions such as cancer, diabetes, autoimmune diseases, and viral risks including SARS-CoV-2, Ebola, Zika, and dengue viruses.
To remain updated, follow Integral Molecular on LinkedIn where you can connect with professionals in the field.
Contact Information
Integral Molecular
Soma Banik, PhD, Director of Public Relations
For further inquiries, please reach out directly.
Frequently Asked Questions
What is Paratope-PLUS™?
Paratope-PLUS™ is a CDR-scanning service launched by Integral Molecular to enhance antibody patent claims and support antibody engineering strategies.
How does Paratope-PLUS™ work?
This service uses high-throughput mutagenesis to mutate each residue of an antibody's CDRs, identifying variants that maintain or enhance functionality.
Why is Paratope-PLUS™ important?
It addresses the new patent landscape post-Supreme Court decisions, helping uphold strong protection for antibody intellectual property.
Who can benefit from this technology?
Antibody developers looking for robust patent protection and better therapeutic designs will find this service particularly beneficial.
Where can I find more information about Integral Molecular?
You can find more details about Integral Molecular and its services on their official website and through their LinkedIn profile.
